Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
3SBio ( (HK:1530) ) has provided an update.
3SBio Inc. has successfully completed the placement of 105,169,500 new shares, raising approximately HK$3,086.84 million. The proceeds will be used primarily for research and development expenditures, including advancing clinical research on innovative drug candidates and supporting global infrastructure, with a portion allocated to working capital and corporate purposes. This strategic move is expected to enhance the company’s market reach and support its ongoing operations and strategic initiatives over the next three years.
The most recent analyst rating on (HK:1530) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc. operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. The company is primarily engaged in the research and development of innovative drug candidates, with a market focus on expanding clinical research both in China and the United States.
Average Trading Volume: 30,478,951
Technical Sentiment Signal: Buy
Current Market Cap: HK$71.96B
For a thorough assessment of 1530 stock, go to TipRanks’ Stock Analysis page.